Muhammed KIZILGÜL, Erman ÇAKAL, Muhammed Erkam SENCAR, Hayri BOSTAN, Sema HEPŞEN, Pınar AKHANLI, Hakan DÜĞER, Bekir UÇAN

The evaluation of breast findings detected through different visualisation techniques in acromegaly patients — a retrospective study

Background/aim: It is known that the increased growth hormone (GH) and insulin-like growth factor-1 (IGF-1) have mitogenic and antiapoptotic properties in breast cells in acromegaly. Our study aims to evaluate breast findings in patients with acromegaly by comparing them to the control group. Materials and methods: Sixty-one patients followed with acromegaly diagnosis and 180 healthy controls were included in our study. Demographic data, laboratory results, Breast Imaging-Reporting and Data System (BI-RADS) scores, and breast density evaluated via mammography, malign and benign breast lesions evaluated via mammography, breast ultrasonography (USG), and breast magnetic resonance imaging (MRI) of patients were compared to the control group. Results: While BI-RADS scores were similar in patient and control groups, breast density in acromegaly patients was found out to be higher compared to the control group (p = 0.754, p = 0.001, respectively). In acromegaly patients, the breast calcification rate was higher than controls (p = 0.021). t was observed that mass frequency in USG in acromegaly patients increased when GH level increased as well (p = 0.021). No difference was detected between benign and malign breast lesions diagnosed histopathologically (p = 0.031, p = 0.573, respectively). There was not any difference in terms of BI-RADS scores, breast types, and breast lesions in acromegaly patients that were in remission and not in remission (p > 0.05). Conclusion: Benign and malign breast lesions were found out to be similar to the control group, although breast density rate was detected to be higher in acromegaly patients. A regular follow-up is required in these patients via suitable breast visualization techniques considering their age and clinical status due to mass formation risk derived from increased GH level and extreme breast density despite the absence of any detected breast lesion frequency in acromegaly patients.Key words: Acromegaly, breast density, breast neoplasm, breast cancer

PDF

___

1. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LØ, Laurberg P et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. European Journal of Endocrinology 2016; 175 (3): 181– 190. doi:10.1530/EJE-16-0117
2. Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M et al. Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. The Journal of Clinical Endocrinology and Metabolism 2018; 103 (6): 2182– 2188. doi:10.1210/jc.2017-02457
3. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P et al. Acromegaly. Nature Reviews Disease Primers 2019; 5 (1): 20. doi:10.1038/s41572-019-0071-6
4. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363 (9418): 1346–1353. doi:10.1016/ S0140-6736(04)16044-3
5. Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Practice and Research Clinical Endocrinology and Metabolism 2008; 22 (4): 639–657. doi:10.1016/j. beem.2008.08.011
6. Prisco M, Romano G, Peruzzi F, Valentinis B, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Hormone and Metabolic Research 1999; 31 (2-3): 80–89. doi:10.1055/s-2007-978703
7. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2095–2128. doi:10.1016/S0140-6736(12)61728-0
8. Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Hormone and IGF Research 2006; 16 (5-6): 277–289. doi:10.1016/j. ghir.2006.09.006
9. Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH et al. Acromegaly: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 2014; 99 (11): 3933–3951. doi:10.1210/jc.2014-2700
10. D’Orsi CJ, Mendelson EB, Morris EA, et al. ACR BI-RADS: Breast Imaging Reporting and Data System. 5th ed. Reston, Va: American College of Radiology, 2012, n.d.
11. Moshina N, Sebuødegård S, Lee CI, Akslen LA, Tsuruda KM et al. Automated Volumetric Analysis of Mammographic Density in a Screening Setting: Worse Outcomes for Women with Dense Breasts. Radiology 2018; 288 (2): 343–352. doi:10.1148/ radiol.2018172972
12. Wanders JOP, Holland K, Veldhuis WB, Mann RM, Pijnappel RM et al. Volumetric breast density affects performance of digital screening mammography. Breast Cancer Research and Treatment 2017; 162 (1): 95–103. doi:10.1007/s10549-016- 4090-7
13. Vachon CM, van Gils CH, Sellers TA, Ghosh K, Pruthi S et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Research 2007; 9 (6): 217. doi:10.1186/bcr1829
14. Sprague BL, Conant EF, Onega T, Garcia MP, Beaber EF et al. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study. Annals of Internal Medicine 2016; 165 (7): 457–464. doi:10.7326/M15-2934
15. Boren WL, Hunter TB, Bjelland JC, Hunt KR. Comparison of breast consistency at palpation with breast density at mammography. Investigative Radiology 1990; 25 (9): 1010– 1011. doi:10.1097/00004424-199009000-00011
16. Stomper PC, D’Souza DJ, DiNitto PA, Arredondo MA. Analysis of parenchymal density on mammograms in 1353 women 25- 79 years old. American Journal of Roentgenology 1996; 167 (5): 1261–1265. doi:10.2214/ajr.167.5.8911192
17. Tagliafico A, Calabrese M, Tagliafico G, Resmini E, Martinoli C et al. Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. European Journal of Endocrinology 2011; 164 (3): 335–340. doi:10.1530/EJE-10- 0896
18. Hada M, Oh H, Pfeiffer RM, Falk RT, Fan S et al. Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. Breast Cancer Research 2019; 21 (1): 81. doi:10.1186/s13058-019-1162-8
19. Boguszewski CL, Boguszewski MC da S. Growth Hormone’s Links to Cancer. Endocrine Reviews 2019; 40 (2): 558–574. doi:10.1210/er.2018-00166
20. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clinical Endocrinology 1998; 49 (4): 441–445. doi:10.1046/j.1365-2265.1998.00536.x
21. Wolinski K, Stangierski A, Dyrda K, Nowicka K, Pelka M et al. Risk of malignant neoplasms in acromegaly: a case–control study. Journal of Endocrinological Investigation 2017; 40 (3): 319–322. doi:10.1007/s40618-016-0565-y
22. Petroff D, Tönjes A, Grussendorf M, Droste M, Dimopoulou C et al. The Incidence of Cancer Among Acromegaly Patients: Results From the German Acromegaly Registry. Journal of Clinical Endocrinology and Metabolism 2015; 100 (10): 3894– 3902. doi:10.1210/jc.2015-2372
23. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998; 83 (8): 2730– 2734. doi:10.1210/jcem.83.8.5007
24. Nabarro JD. Acromegaly. Clinical Endocrinology 1987; 26 (4): 481–512. doi:10.1111/j.1365-2265.1987.tb00805.x
25. Murphy N, Knuppel A, Papadimitriou N, Martin RM, Tsilidis KK et al. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with -430 000 women. Annals of Oncology 2020; 31 (5): 641–649. doi:10.1016/j. annonc.2020.01.066
26. Dagdelen S, Cinar N, Erbas T. Increased thyroid cancer risk in acromegaly. Pituitary 2014; 17 (4): 299–306. doi:10.1007/ s11102-013-0501-5
27. Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010; 13 (3): 242–248. doi:10.1007/s11102-010-0224-9